MDC1 and cancer: We also observed that the cisplatin sensitivity restored by si-MDC1 in BIN1-deficient cancer cells was compromised by carbobenzoxy-valyl-alanyl-aspartyl fluoromethyl ketone (z-VAD-fmk) (20 μM), a cell-permeable pan-caspase inhibitor (Figure 3B).